Preprint Case Report Version 1 Preserved in Portico This version is not peer-reviewed

Sintilimab-Induced Diabetic Ketoacidosis in A Patient with Radiation and Multichemorefractory Penile Cancer: A Case Report and Literature Review

Version 1 : Received: 19 July 2022 / Approved: 20 July 2022 / Online: 20 July 2022 (06:09:13 CEST)

How to cite: Lv, C.; Wu, C.; Zhang, Y.; Li, W.D.; Wang, X.S.; Liang, L. Sintilimab-Induced Diabetic Ketoacidosis in A Patient with Radiation and Multichemorefractory Penile Cancer: A Case Report and Literature Review. Preprints 2022, 2022070296 (doi: 10.20944/preprints202207.0296.v1). Lv, C.; Wu, C.; Zhang, Y.; Li, W.D.; Wang, X.S.; Liang, L. Sintilimab-Induced Diabetic Ketoacidosis in A Patient with Radiation and Multichemorefractory Penile Cancer: A Case Report and Literature Review. Preprints 2022, 2022070296 (doi: 10.20944/preprints202207.0296.v1).

Abstract

Penile squamous cell carcinoma (SCC) is a rare disease. Treatment options for advanced penile cancer are often limited and prognosis remains poor. We reported a 52-year-old male recurrent and metastatic penile SCC patient with high PD-L1 expression(90%) and TMB(14.4 muts/Mb). He had undergone penectomy, bilateral inguinal lymph node dissection and excision of the abdominal wall mass during two surgeries. Despite cisplatin-based concurrent chemoradiotherapy and sequential chemotherapy with docetaxel plus cisplatin were then carried out, the carcinoma still had progressed. The patient then obtained progression free survival exceeding 32 months with continuous sintilimab, although new onset of ICI-induced diabetes after 24 cycles of sintilimab and required sustained insulin treatment. He didn’t have positive type 1 diabetes associated autoantibodies, but had susceptible HLA genotype DR3-DQ2 haplotype. This is the first patient with radiation and multichemorefractory penile SCC obtained remarkable anti-tumor effect of partial regression exceeding 32 months during continuous sintilimab.

Keywords

Autoimmune diabetes; PD-1 inhibitor; Sintilimab; Penile carcinoma

Subject

MEDICINE & PHARMACOLOGY, Urology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.

We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.